Unique Hybrid Implant First Installed to Cat

MOSCOW, July 17, 2019 /PRNewswire/ — Scientific team of a small innovative enterprise Biomimetix, based on the National University of Science and Technology MISIS together with their colleagues from the N.N. Blokhin National Medical Research Centre of oncology developed a unique implant to replace the damaged bone fragment. The implant, which imitates real bone structure, was installed to a domestic cat with osteosarcoma by surgeons of the veterinary clinic “Biocontrol”. According to postoperative observations, the implant fits well, the dynamics of recovery of the mustachioed patient is positive.

Young scientists from a small innovative enterprise based on the National University of Science and Technology MISIS has been developing biocompatible bone implants based on ultrahigh molecular weight polyethylene (UHMWPE). The core of the hybrid implant is made of porous ultra-high molecular weight polyethylene, and the frame is made of titanium alloy printed on a 3D printer. Such a structure imitates the structure of the real bone, where UHMWPE corresponds to the porous internal, trabecular part, and titanium alloy imitates the solid external, cortical part.

In March-April 2019 the implant was installed to a domestic cat Lapunya (~Sweetie in English) after the removal of a 6 cm bone fragment, damaged with osteosarcoma. In collaboration with  N. Blokhin National Medical Research Centre of oncology a unique bone-cellular structure was developed: Biomimetix’ specialists manufactured the implant, and their colleagues from the Laboratory of Cellular Immune System doped it with the cells extracted from bone marrow of the cat, to shorten the adaptation period. The surgery was carried out by surgeons of the veterinary clinic “Biocontrol”.

“Our implant almost completely corresponds to the usual bone. First of all, this means that it will not take on excessive load, so the bone at the place of its attachment will not become brittle, as it often happens with metal implants. In addition, the polymer surface of the implant is convenient to dope it with the patient’s own cells, which significantly accelerates survival. This is especially important given the fact that we cannot explain pets that at the time of recovery the limb should be protected,” – Fyodor Senatov, CEO of Biomimetix, researcher at NUST MISIS Center of Composite Materials.

According to the postoperative observations, in July 2019 the implant fits well, the dynamics of recovery is positive and the cat can walk normally. Thus, the implantation of such a hybrid cell-engineering implant becomes a good alternative to the traditional radical treatment – amputation, as well as to much more complex metal implants.

View original content:http://www.prnewswire.com/news-releases/unique-hybrid-implant-first-installed-to-cat-300886521.html

SOURCE The National University of Science and Technology MISiS

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago